ESA-sensitive patients derive survival benefits from the full correction of anemia, whereas patients with ESA resistance (which is a predictor of poor survival) may be harmed by the high doses of ESA prescribed in the attempt to increase Hb levels [44, 45]; however, this is still under debate [46]. This evidence concerns the gene GSTM1 and anemia.